DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

Nutrition & Diabetes is a leading open-access journal published by SPRINGERNATURE that has been at the forefront of research since its inception in 2011. With a dedicated focus on the intricate relationship between nutrition and metabolic disorders, this journal serves as an essential resource for researchers, healthcare professionals, and students committed to advancing knowledge in the fields of endocrinology, diabetes, and internal medicine. The journal is recognized for its high impact, reflected in its prestigious Q1 ranking in both Endocrinology, Diabetes and Metabolism and Internal Medicine, as well as its strong performance in Scopus rankings, placing it within the top echelons of related disciplines. Based in the United Kingdom, Nutrition & Diabetes is committed to publishing high-quality, peer-reviewed research that addresses current challenges and innovations in nutrition science and metabolic health. Open Access since 2011, the journal promotes the dissemination of critical findings, ensuring that vital research is accessible to a global audience, thus driving further advancements in this important and evolving field.

Diabetes Technology & Therapeutics is a leading journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of diabetes management through innovative technologies and therapeutic strategies. With an impressive impact factor and recognized as a Q1 journal in Endocrinology, Diabetes and Metabolism, as well as Medical Laboratory Technology, it occupies a pivotal position in the academic landscape. This esteemed publication features a comprehensive range of articles that cover cutting-edge research, clinical applications, and developments in diabetes care from 1999 to 2024, making it a critical resource for researchers, health professionals, and students alike. The journal is committed to fostering dialogue between disciplines, especially given its strong rankings in various scientific categories including the 98th percentile in Medical Laboratory Technology. By opting for subscription-based access, readers gain insight into the latest innovations that are shaping diabetes technology and treatment paradigms, thereby enhancing patient outcomes and advancing the scientific community's understanding of this complex disease.

Diabetes Stoffwechsel und Herz, published by VERLAG KIRCHHEIM, is a distinguished journal that focuses on the interdisciplinary field of diabetes research, cardiology, and metabolic disorders. With its dedicated approach, the journal aims to disseminate cutting-edge findings and foster innovative discussions among researchers and practitioners in the healthcare community. Despite its discontinuation in Scopus coverage since 2017, the journal continues to hold significance in advancing knowledge regarding the intricate relationship between diabetes and cardiovascular health. It offers researchers a platform to explore the biochemical, genetic, and clinical aspects of endocrinology, while also catering to the needs of professionals aiming to apply the latest research in their practice. The journal’s rankings, which place it in the lower percentiles across various relevant categories, reflect a unique opportunity for contributors looking to impact a niche yet vital area of medicine. As the field evolves, Diabetes Stoffwechsel und Herz remains committed to enriching the dialogue surrounding these critical health issues.

The British Journal of Diabetes, published by the Association of British Clinical Diabetologists, is a premier journal dedicated to advancing the understanding, prevention, and management of diabetes. With an ISSN of 2397-6233, this journal aims to disseminate high-quality research findings, clinical studies, and reviews that address the complexities of diabetes care and research. While currently not available as an open access option, the journal is committed to enhancing the visibility of cutting-edge diabetes research for healthcare professionals and academics. Located in the heart of England, this journal plays a crucial role in bridging the gap between clinical practice and research innovation, making it an essential resource for practitioners, researchers, and students alike. The British Journal of Diabetes is determined to contribute significantly to the global dialogue on diabetes, as it covers a wide spectrum of topics from epidemiology and public health to novel therapeutic strategies and patient management approaches.

The Journal of Diabetology, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Since its inception in 2010, this Open Access journal has provided researchers and healthcare professionals with a wealth of knowledge through rigorous peer-reviewed articles that cover clinical research, epidemiology, and innovative treatment strategies. With an E-ISSN of 2078-7685 and a commitment to disseminating high-quality scientific work, the journal plays a pivotal role in contributing to the global discourse on diabetes care and prevention. Its dedication to accessibility enhances its impact on both established scholars and emerging researchers seeking to make meaningful contributions in the field. By fostering a collaborative environment, the Journal of Diabetology aims to bridge the gap between research and practical implementation, ultimately improving outcomes for individuals affected by diabetes.

Journal of Diabetes Investigation is a prestigious open-access journal published by WILEY, dedicated to advancing knowledge in the fields of Endocrinology, Diabetes, and Metabolism. With its ISSN 2040-1116 and E-ISSN 2040-1124, the journal provides a vital platform for researchers, healthcare professionals, and students to disseminate high-quality research, foster innovative ideas, and engage with cutting-edge developments in diabetes investigation. Since its inception in 2010, the journal has established a solid reputation, ranking in Q2 for Endocrinology and Diabetes and Metabolism, and Q1 for both Internal Medicine and Miscellaneous Medicine categories in 2023. Its Scopus rankings further underscore its impact, notably at the 76th percentile in Internal Medicine. The open access model, adopted in 2014, ensures that vital information is freely available, promoting global collaboration and knowledge sharing. The journal is not only a reflection of Australia's commitment to medical research but also a beacon for advancements that can ultimately enhance patient outcomes in diabetes care.

DIABETIC MEDICINE is a leading peer-reviewed journal published by Wiley, dedicated to advancing the field of endocrinology, specifically focusing on the pathophysiology, management, and prevention of diabetes mellitus and its complications. With an impressive impact factor reflecting its significant role in shaping clinical practice and research, DIABETIC MEDICINE holds a prominent position among its peers, categorized in the Q1 quartiles for Endocrinology, Diabetes and Metabolism, and Internal Medicine. Since its inception in 1984, the journal has provided a platform for rigorous and innovative research, fostering collaborative efforts among researchers, clinicians, and students to enhance diabetes care. The journal is esteemed for its high-ranking performance in Scopus, highlighted by its ranking of #33 in Internal Medicine and #64 in Endocrinology, Diabetes, and Metabolism. By offering insightful access to groundbreaking studies and reviews, DIABETIC MEDICINE plays a crucial role in informing policy and improving medical outcomes for individuals with diabetes, making it an essential resource for those in medical and clinical research fields.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.

The Journal of Diabetes, published by WILEY, is a premier Open Access platform since 2022, dedicated to advancing knowledge in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 1753-0393 and an E-ISSN of 1753-0407, this journal provides a vital resource for researchers and practitioners looking to keep up with the latest findings and trends in diabetes management and treatment. As of 2023, it holds a commendable Q2 rating in its category and ranks #78 out of 244 in the Scopus classification, placing it in the 68th percentile, thus affirming its significance in the academic community. Covering a timeline from 2009 to 2024, the journal invites submissions that contribute to the understanding of diabetes pathophysiology, innovative therapies, and clinical practices, making it an essential read for anyone dedicated to improving patient outcomes in diabetes care.